The most clinically advanced BH3-mimetic drug is Venetoclax, which selectively targets BCL-2 and is approved by several regulatory bodies worldwide for the treatment of chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) [13]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.